Join
Live feed
·
PRReleasevia Quantisnow
Compugen Ltd. logo

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

ByQuantisnow·Wall Street's wire, on your screen.
CGEN· Compugen Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGEN (Compugen Ltd.) and more on Quantisnow.